Japan Ahead: Takeda Pharmaceutical CEO

The video discusses the impact of yen depreciation on business growth, focusing on innovation and global revenue. It highlights the company's strategy for shareholder returns and targeted acquisitions, emphasizing therapy areas and pipeline development. The dengue vaccine program is detailed, with plans for global launch. The impact of Vyvanse's generic competition is addressed, with a positive long-term growth outlook. The importance of innovation and global commercialization for Japan's growth is underscored.

What is the primary factor driving the company's growth according to the text?

How does the depreciation of the yen impact the company's revenue?

What are the four therapy areas the company is focusing on for business development?

How does the company plan to enrich its product pipeline?

What is the expected efficacy of the dengue vaccine after 4.5 years?

What challenges does the company anticipate in 2023 regarding Vyvanse?

What is the company's strategy for innovation and commercialization in Japan?